 | | Vol. 14.04 – 3 February, 2023 |
| |
|
|
| Using RNA-seq, scientists revealed that SMAD3 knockdown decreased levels of androgen receptor (AR) and AR target genes, whereas SMAD4 or SMAD2 knockdown had little or no effect.
[Nucleic Acids Research] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers explored the phosphatidylinositol-5-phosphate 4-kinases (PI5P4K) and demonstrated that the PI5P4Kα isoform influenced androgen receptor signaling, which supported prostate cancer cell survival.
[Science Advances] |
|
|
|
| Investigators demonstrated that two multi-target natural products, cannabidiol and cannabigerol, suppressed hormone refractory prostate cancer development in the transgenic adenocarcinoma of the mouse prostate model by reprogramming metabolic and oncogenic signaling.
[Pharmacological Research] |
|
|
|
| The authors showed that neuroendocrine prostate or lung cancer cells possessed mostly fragmented mitochondria with low membrane potential and relied on glycolysis for energy metabolism.
[Cell Reports] |
|
|
|
| Scientists identified the essential role of serum/glucocorticoid regulated kinase 2 (SGK2) in promoting prostate cancer metastasis by inhibiting ferroptosis.
[Cell Death & Disease] |
|
|
|
| In primary human prostate cancer cells-derived from castration-resistant prostate cancer patients, WM-3835 potently inhibited cell viability, proliferation, cell cycle progression, and in vitro cell migration.
[Cell Death & Disease] |
|
|
|
| Investigators demonstrated using multiple independent clinical cohorts that the glycosyltransferase enzyme GALNT7 was upregulated in prostate cancer tissue.
[Oncogene] |
|
|
|
| Circulating tumor cells were analyzed in patients with metastatic prostate cancer during radiotherapy with CellSearch, multi-color flow cytometry, and imaging cytometry.
[International Journal of Cancer] |
|
|
|
| Gain‑and‑loss experiments were used to investigate the effects of VIM‑AS, a cancer‑specific long non‑coding RNA, on the proliferation and anti‑androgen therapy of LNCaP and C4‑2 cells.
[International Journal of Oncology] |
|  |
|
|
|
| The authors highlight recent evidence on the epigenetic mechanisms underlying the emergence of lineage plasticity and neuroendocrine differentiation in treatment-resistant prostate tumors.
[Nature Communications] |
|
|
|
| Scientists explore the epidemiological links between obesity and metabolic syndrome and prostate cancer (PCa), the evidence for altered circulating lipids in PCa and their potential role as biomarkers, as well as novel therapeutic strategies for targeting lipids in men with PCa.
[Therapeutic Advances in Medical Oncology] |
|
|
|
|
| The Prostate Cancer Foundation (PCF) announced the 2022 Class of PCF Team Challenge Award recipients and a total of more than $12 million in funding for innovative prostate cancer research.
[Prostate Cancer Foundation] |
|
|
|
|
| April 25 – 26, 2023
London, England, United Kingdom |
|
|
|
|
|
| | Novartis – East Hanover, New Jersey, United States |
|
|
|
| | University of Texas MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
| | University of Texas MD Anderson Cancer Center – Houston, Texas, United States |
|
|
|
| | Pompeu Fabra University – Barcelona, Spain |
|
|
|
| | Stanford Medicine – Stanford, California, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
